By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
CSL Behring Release: HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available In The United States For Patients With Hereditary Angioedema 7/25/2017 6:41:40 AM
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) 7/21/2017 8:46:46 AM
FDA Accepts CSL Behring's Supplemental Biologics License Application For Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication 7/19/2017 7:47:16 AM
CSL Behring Release: New Data Demonstrate Prophylactic Treatment With IDELVION Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B 7/12/2017 7:44:45 AM
CSL Behring Release: New Findings Show AFSTYLA Provides Long-Lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Hemophilia A 7/10/2017 7:21:23 AM
CSL Behring Release: FDA Approves HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), First And Only Subcutaneous Preventive Treatment For Hereditary Angioedema 6/26/2017 6:31:40 AM
CSL Behring Release: Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies 3/31/2017 9:39:07 AM
CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients 3/30/2017 7:32:36 AM
The New England Journal of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients 3/23/2017 6:16:33 AM
CSL Behring Release: Largest Ever CIDP Clinical Study Completed 3/1/2017 8:13:56 AM